All Events

Upcoming Events

12696 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 18 Mar 2019 18 Mar 2019 18 Mar 2019 18 Mar 2019 12:30:00 14:00:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. </div> <div>An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC</div> <div> OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00105 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 38071 Welcome and Introductions 12:30:00 20213 1 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 38072 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 12:35:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 38073 Q & A 13:30:00 20213 1 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 38075 Close 14:00:00 20213 Dr Raffaele Califano Dr Raffaele Califano is Consultant in Medical Oncology at The Christie and University Hospital of South Manchester, Manchester, UK. He graduated in Medicine and Surgery from the University of Perugia, Italy, in 2003, and completed his specialist training in Medical Oncology, in 2007. Previously, Raffaele Califano worked as a Clinical Research Fellow with the lung and melanoma team at The Christie (2008–2012) where he trained in advanced trial design and management, and was an investigator for several lung cancer and melanoma clinical trials. Raffaele Califano specialises in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. He serves as Chairman of the Publishing Working Group of the European Society for Medical Oncology (ESMO) and is also a member of the ESMO Educational Committee Steering Group. Raffaele Califano is author of several papers published in peer-reviewed international journals and has been an invited speaker at several national and international meetings. Dr Califano is a member of the Editorial Board of ESMO Open: Cancer Horizons, the European Journal of Cancer, Cancer Treatment Reviews and Cancer Treatment Communications,  and is also peer reviewer for a number of medical journals. The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust, Manchester. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/califano-raffaele-2_medium_portrait.jpg 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 12520 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 19 Mar 2019 19 Mar 2019 19 Mar 2019 19 Mar 2019 19:00:00 20:30:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.</div> <div> </div> <div>An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC. OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div> </div> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC. OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00108 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 37887 Welcome and Introductions 19:00:00 59830 1 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 37888 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 19:05:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 37889 Q & A 20:00:00 59830 1 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 37891 Close 20:30:00 59830 Professor Samreen Ahmed Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016. Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group.   Professor Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Prof Samreen Ahmed.jpg 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 12540 0 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response UK uk-UA 20 Mar 2019 20 Mar 2019 20 Mar 2019 20 Mar 2019 19:00:00 20:30:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.</div> <div> </div> <div> An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC</div> <div> OBJECTIVES:</div> <ul> <li>To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC</li> <li>To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes </li> <li>To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.</li> </ul> <div style="text-align:center"><a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">Click here</a> for Prescribing Information.</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC OBJECTIVES: To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC. Click here for Prescribing Information. For KEYTRUDA ▼(pembrolizumab) Prescribing Information and full licenced indications <a href="http://www.msdproduct.co.uk/api/keytrudalung.pdf">click here</a> <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-PDO-00111 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 2 Commercial - Unbranded 38066 Welcome and Introductions 19:00:00 60281 1 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 38067 The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response 19:05:00 59831 2 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 38068 Discussion and questions. 20:00:00 60281 1 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 38069 Close 20:30:00 60281 Dr Thomas Newsom-Davis Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He is a member of the National Cancer Research Institutes lung cancer clinical study group and the British Thoracic Oncology Group steering committee. Dr Newsom-Davis leads lung cancer for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. Dr Newsom-Davis has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.   Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Tom Newsom-David photo.jpg (1).png 59831 Dr Corey J. Langer Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.   Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is also Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). For the past 31 years, since completing his fellowship, Professor Langer has led or co-led over 120 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC). Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 220 peer-reviewed papers. Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine. http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Langer_Photo.JPG 13138 0 TRANSFORMATION - Adjuvant Melanoma: Time for Action TRANSFORMATION - Adjuvant Melanoma: Time for Action UK uk-UA 22 Mar 2019 22 Mar 2019 22 Mar 2019 22 Mar 2019 10:00:00 14:30:00 Greenwich Mean Time <div style="text-align:center">This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. </div> <div>MSD are hosting an event to launch KEYTRUDA ▼(pembrolizumab) for the adjuvant treatment for melanoma following marketing authorisation in the UK. The meeting aims to explore the progress made in the treatment of melanoma including the opportunities that are now available within the new adjuvant setting. <ul> <li>To explore the clinical data that has led to the recent approvals of adjuvant treatments for melanoma, in order to enhance the knowledge and understanding of those involved in the melanoma MDT</li> <li>To discuss the current clinical treatment considerations in the management of adjuvant melanoma patients</li> <li>To raise awareness of the learnings that have been gained from the introduction of adjuvant treatment within other types of cancer (e.g. breast cancer)</li> </ul> KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection. <a href="http://www.msdproduct.co.uk/api/keytrudamelanoma.pdf">Click here</a> for prescribing information</div> This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting. MSD are hosting an event to launch KEYTRUDA ▼(pembrolizumab) for the adjuvant treatment for melanoma following marketing authorisation in the UK. The meeting aims to explore the progress made in the treatment of melanoma including the opportunities that are now available within the new adjuvant setting. To explore the clinical data that has led to the recent approvals of adjuvant treatments for melanoma, in order to enhance the knowledge and understanding of those involved in the melanoma MDT To discuss the current clinical treatment considerations in the management of adjuvant melanoma patients To raise awareness of the learnings that have been gained from the introduction of adjuvant treatment within other types of cancer (e.g. breast cancer) KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection. Click here for prescribing information <table border="0" cellpadding="1" cellspacing="1" style="border-bottom:#000000 1px solid; border-left:#000000 1px solid; border-right:#000000 1px solid; border-top:#000000 1px solid; width:100%"> <tbody> <tr> <td style="text-align:center"> Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK. </td> </tr> </tbody> </table> Master In Progress GB-OOC-00078 Date of preparation: February 2019 N/A Not in use Not in use Not in use Not in use Not in use Concluded ON24 N/A N/A N/A http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIImage.jpg http://webcast-editor-tool3.msd.com/newlmsresponsive/App_Themes/207_Template/images/MCIMainImage.jpg 26 Webconference 26 Webconference 3 Non-Commercial 2 Commercial - Unbranded 5 Webcast 38638 Welcome and Introduction 10:00:00 65667 1 Professor James Larkin Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney. Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008. His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He is a past NIHR National Specialty Lead for Early Phase Cancer Trials as well as past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ Institute of Cancer Research Committee for Clinical Research. He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/ Institute of Cancer Research Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. He is a medical advisor to the patient advocacy group Melanoma UK, a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.   Professor James Larkin MA, FRCP, PhD, FMedSci, Consultant Medical Oncologist, The Royal Marsden Hospital London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/James Larkin Photo.JPG 38645 The Science of Saving Lives: The past, present and future of immunotherapy research in the UK 10:10:00 65679 2 Professor Charles Swanton Professor Charles Swanton completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Professor Swanton combines his laboratory research at the Francis Crick Institute with clinical duties at UCLH and as director of the CRUK UCL Lung Cancer Centre, focussed on how tumours evolve over space and time. Professor Swanton has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell to- cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Professor Swanton was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, Napier Professor in Cancer by the Royal Society in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, and elected Fellow of the Royal Society in 2018. Professor Swanton was awarded the Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017), the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), the Massachusetts General Hospital Cancer Centre Kraft Prize for Excellence in Cancer Research (2018), and the International Association for the Study of Lung Cancer (IASLC) Paul A. Bunn Scientific Award for achievements in lung cancer (2018).   Professor Charles Swanton, FRCP PhD FMedSci, FRS, Francis Crick Institute London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/charles.jpg 38646 Putting Theory into Practice: How adjuvant clinical data translates to everyday treatment for melanoma patients 10:55:00 65667 1 Professor James Larkin Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney. Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008. His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He is a past NIHR National Specialty Lead for Early Phase Cancer Trials as well as past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ Institute of Cancer Research Committee for Clinical Research. He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/ Institute of Cancer Research Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. He is a medical advisor to the patient advocacy group Melanoma UK, a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.   Professor James Larkin MA, FRCP, PhD, FMedSci, Consultant Medical Oncologist, The Royal Marsden Hospital London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/James Larkin Photo.JPG 65680 3 Dr Paul Nathan Dr Paul Nathan is a Consultant Medical Oncologist at Mount Vernon Cancer Centre, Northwood, UK. His specialist interests are the treatment of malignant melanoma and renal cell carcinoma. His clinical training was through Cambridge and London having had an earlier scientific career in academia and the pharmaceutical industry. He chairs the NCRI Bladder and Renal Carcinoma Clinical Studies Group. He is EORTC Uveal Melanoma lead, International Rare Cancer Initiative UK Uveal melanoma lead and chaired the UK guideline group on Uveal Melanoma. He is UK chief investigator and steering committee member for a number of academic and pharma sponsored melanoma and renal carcinoma studies. He has authored many papers and book chapters. He is an advisory board member for a number of pharmaceutical companies. He is a trustee of Melanoma Focus the UK national melanoma charity and Kidney Cancer UK.   Dr Paul Nathan, MBBS, PhD, FRCP, Mount Vernon Cancer Centre Northwood http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/DrPaulNathan Photo.jpg 65681 4 Dr Sophie Papa Dr Sophie Papa is a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Dr Papa undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology. Here group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Dr Papa is a Medical Oncologist with a practice in malignant melanoma and Merkle cell carcinoma. Dr Papa has expertise in the design and delivery of first in man studies including cell therapy trials and is a principal investigator in the GSTT Early Phase Trials Team. She is the lead for skin cancer research and chairs the biological safety committee.       Dr Sophie Papa, MA, MBBS, MRCP, PhD, Guy's and St Thomas' NHS Foundation Trust London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Sophie Papa Photo.jpg 38791 Break 11:55:00 38648 Case by Case: Putting the patients first – a series of patient case scenarios that highlight the current treatment decisions involved in the management of adjuvant melanoma patients 12:10:00 65667 1 Professor James Larkin Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney. Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008. His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He is a past NIHR National Specialty Lead for Early Phase Cancer Trials as well as past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ Institute of Cancer Research Committee for Clinical Research. He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/ Institute of Cancer Research Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. He is a medical advisor to the patient advocacy group Melanoma UK, a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.   Professor James Larkin MA, FRCP, PhD, FMedSci, Consultant Medical Oncologist, The Royal Marsden Hospital London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/James Larkin Photo.JPG 65680 3 Dr Paul Nathan Dr Paul Nathan is a Consultant Medical Oncologist at Mount Vernon Cancer Centre, Northwood, UK. His specialist interests are the treatment of malignant melanoma and renal cell carcinoma. His clinical training was through Cambridge and London having had an earlier scientific career in academia and the pharmaceutical industry. He chairs the NCRI Bladder and Renal Carcinoma Clinical Studies Group. He is EORTC Uveal Melanoma lead, International Rare Cancer Initiative UK Uveal melanoma lead and chaired the UK guideline group on Uveal Melanoma. He is UK chief investigator and steering committee member for a number of academic and pharma sponsored melanoma and renal carcinoma studies. He has authored many papers and book chapters. He is an advisory board member for a number of pharmaceutical companies. He is a trustee of Melanoma Focus the UK national melanoma charity and Kidney Cancer UK.   Dr Paul Nathan, MBBS, PhD, FRCP, Mount Vernon Cancer Centre Northwood http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/DrPaulNathan Photo.jpg 65681 4 Dr Sophie Papa Dr Sophie Papa is a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Dr Papa undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology. Here group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Dr Papa is a Medical Oncologist with a practice in malignant melanoma and Merkle cell carcinoma. Dr Papa has expertise in the design and delivery of first in man studies including cell therapy trials and is a principal investigator in the GSTT Early Phase Trials Team. She is the lead for skin cancer research and chairs the biological safety committee.       Dr Sophie Papa, MA, MBBS, MRCP, PhD, Guy's and St Thomas' NHS Foundation Trust London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Sophie Papa Photo.jpg 65836 5 Jackie Hodgetts Jackie Hodgetts is a Nurse Clinician at The Christie Hospital in Manchester, where she has worked since 1988 when she was employed as a Research Nurse working with lung cancer and melanoma patients. In 2009 she completed a Master’s degree in Clinical Practice, and since then has worked with melanoma patients, assessing and supporting them through treatment, as well as managing their toxicities. Jackie has been involved in multiple trials of melanoma treatments, including the early studies of BRAF inhibitors and other targeted therapies. She was also involved in early studies with CTLA-4 and anti-PD-1/PD-L1 antibodies and has since treated many patients with these therapies. Consequently she has developed expertise in melanoma treatments and the management of their side effects. Jackie has published two articles on melanoma in Cancer Nursing Practice and The Nursing Times, and has jointly published a paper on understanding and managing immune-related adverse events.   Jackie Hodgetts, Nurse Clinician, The Christie Hospital Manchester http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Jackie Hodgetts_ Photo.jpg 38792 Break 13:10:00 38651 Patient first: The role of patient advocacy groups within clinical trials and patient education 13:40:00 65843 6 Simon Rodwell Following earlier careers as a Royal Navy submariner, then in aerospace, telecoms and China business consultancy, Simon Rodwell helped set up Melanoma Focus in 2012 in memory of his late wife, Professor Sheila Bingham OBE, an MRC scientist who died of melanoma in 2009. Simon is a lay member of several melanoma trial management committees, attends the NCRI Skin Cancer Clinical Studies Group and has produced & scripted videos for patients, including Taking Part in Clinical Trials: how patients can make a difference (2015).   Simon Rodwell, Chief Executive, Melanoma Focus http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Simon Rodwell_ Photo.JPG 38654 Transformational Service Changes: Sharing best practice for service optimisation with the introduction of adjuvant therapies 14:00:00 65836 5 Jackie Hodgetts Jackie Hodgetts is a Nurse Clinician at The Christie Hospital in Manchester, where she has worked since 1988 when she was employed as a Research Nurse working with lung cancer and melanoma patients. In 2009 she completed a Master’s degree in Clinical Practice, and since then has worked with melanoma patients, assessing and supporting them through treatment, as well as managing their toxicities. Jackie has been involved in multiple trials of melanoma treatments, including the early studies of BRAF inhibitors and other targeted therapies. She was also involved in early studies with CTLA-4 and anti-PD-1/PD-L1 antibodies and has since treated many patients with these therapies. Consequently she has developed expertise in melanoma treatments and the management of their side effects. Jackie has published two articles on melanoma in Cancer Nursing Practice and The Nursing Times, and has jointly published a paper on understanding and managing immune-related adverse events.   Jackie Hodgetts, Nurse Clinician, The Christie Hospital Manchester http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Jackie Hodgetts_ Photo.jpg 65855 7 Dr Mark Harries Dr Mark Harries is a Consultant Medical Oncologist at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.  He specialises in the treatment of Breast Cancer and Melanoma.   He graduated from Cambridge University and underwent clinical training at the Royal London Hospital.  He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London. His research interests include immunotherapy for melanoma and breast cancer as well as clinical trials of new biological agents for these diseases.   He has published many papers and presents regularly at national and international conferences. He is oncology editor for the International Journal of Clinical Practice.   Dr Mark Harries, MA MB BChir PhD FRCP, Consultant Medical Oncologist, Guy’s & St Thomas’ Hospitals NHS Foundation Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Mark Harries_ photo.jpg 65667 Professor James Larkin Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney. Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008. His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He is a past NIHR National Specialty Lead for Early Phase Cancer Trials as well as past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ Institute of Cancer Research Committee for Clinical Research. He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/ Institute of Cancer Research Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. He is a medical advisor to the patient advocacy group Melanoma UK, a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.   Professor James Larkin MA, FRCP, PhD, FMedSci, Consultant Medical Oncologist, The Royal Marsden Hospital London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/James Larkin Photo.JPG 65679 Professor Charles Swanton Professor Charles Swanton completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Professor Swanton combines his laboratory research at the Francis Crick Institute with clinical duties at UCLH and as director of the CRUK UCL Lung Cancer Centre, focussed on how tumours evolve over space and time. Professor Swanton has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell to- cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Professor Swanton was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, Napier Professor in Cancer by the Royal Society in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, and elected Fellow of the Royal Society in 2018. Professor Swanton was awarded the Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017), the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), the Massachusetts General Hospital Cancer Centre Kraft Prize for Excellence in Cancer Research (2018), and the International Association for the Study of Lung Cancer (IASLC) Paul A. Bunn Scientific Award for achievements in lung cancer (2018).   Professor Charles Swanton, FRCP PhD FMedSci, FRS, Francis Crick Institute London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/charles.jpg 65680 Dr Paul Nathan Dr Paul Nathan is a Consultant Medical Oncologist at Mount Vernon Cancer Centre, Northwood, UK. His specialist interests are the treatment of malignant melanoma and renal cell carcinoma. His clinical training was through Cambridge and London having had an earlier scientific career in academia and the pharmaceutical industry. He chairs the NCRI Bladder and Renal Carcinoma Clinical Studies Group. He is EORTC Uveal Melanoma lead, International Rare Cancer Initiative UK Uveal melanoma lead and chaired the UK guideline group on Uveal Melanoma. He is UK chief investigator and steering committee member for a number of academic and pharma sponsored melanoma and renal carcinoma studies. He has authored many papers and book chapters. He is an advisory board member for a number of pharmaceutical companies. He is a trustee of Melanoma Focus the UK national melanoma charity and Kidney Cancer UK.   Dr Paul Nathan, MBBS, PhD, FRCP, Mount Vernon Cancer Centre Northwood http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/DrPaulNathan Photo.jpg 65681 Dr Sophie Papa Dr Sophie Papa is a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust (GSTT). Dr Papa undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in solid tumour CAR T-cell cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology. Here group have two areas of study: Firstly, strategies to enhance CAR T-cell clinical translation and secondly, cohort based investigation of mechanism of checkpoint inhibitor driven inflammatory disease. Dr Papa is a Medical Oncologist with a practice in malignant melanoma and Merkle cell carcinoma. Dr Papa has expertise in the design and delivery of first in man studies including cell therapy trials and is a principal investigator in the GSTT Early Phase Trials Team. She is the lead for skin cancer research and chairs the biological safety committee.       Dr Sophie Papa, MA, MBBS, MRCP, PhD, Guy's and St Thomas' NHS Foundation Trust London http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Sophie Papa Photo.jpg 65836 Jackie Hodgetts Jackie Hodgetts is a Nurse Clinician at The Christie Hospital in Manchester, where she has worked since 1988 when she was employed as a Research Nurse working with lung cancer and melanoma patients. In 2009 she completed a Master’s degree in Clinical Practice, and since then has worked with melanoma patients, assessing and supporting them through treatment, as well as managing their toxicities. Jackie has been involved in multiple trials of melanoma treatments, including the early studies of BRAF inhibitors and other targeted therapies. She was also involved in early studies with CTLA-4 and anti-PD-1/PD-L1 antibodies and has since treated many patients with these therapies. Consequently she has developed expertise in melanoma treatments and the management of their side effects. Jackie has published two articles on melanoma in Cancer Nursing Practice and The Nursing Times, and has jointly published a paper on understanding and managing immune-related adverse events.   Jackie Hodgetts, Nurse Clinician, The Christie Hospital Manchester http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Jackie Hodgetts_ Photo.jpg 65843 Simon Rodwell Following earlier careers as a Royal Navy submariner, then in aerospace, telecoms and China business consultancy, Simon Rodwell helped set up Melanoma Focus in 2012 in memory of his late wife, Professor Sheila Bingham OBE, an MRC scientist who died of melanoma in 2009. Simon is a lay member of several melanoma trial management committees, attends the NCRI Skin Cancer Clinical Studies Group and has produced & scripted videos for patients, including Taking Part in Clinical Trials: how patients can make a difference (2015).   Simon Rodwell, Chief Executive, Melanoma Focus http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Simon Rodwell_ Photo.JPG 65855 Dr Mark Harries Dr Mark Harries is a Consultant Medical Oncologist at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.  He specialises in the treatment of Breast Cancer and Melanoma.   He graduated from Cambridge University and underwent clinical training at the Royal London Hospital.  He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London. His research interests include immunotherapy for melanoma and breast cancer as well as clinical trials of new biological agents for these diseases.   He has published many papers and presents regularly at national and international conferences. He is oncology editor for the International Journal of Clinical Practice.   Dr Mark Harries, MA MB BChir PhD FRCP, Consultant Medical Oncologist, Guy’s & St Thomas’ Hospitals NHS Foundation Trust http://webcast-editor-tool3.msd.com/filesdownload/SpeakersImages/Mark Harries_ photo.jpg

No events listed at present, please check again soon.

Past Events

Watch events on demand, download related materials and catch up on selected highlights from past events

No events listed at present, please check again soon.

GB-NON-00477 | Date of preparation: February 2019